Compounded semaglutide is not FDA-approved and has not been evaluated for safety, potency, or sterility by the FDA. It was legally available during the period when semaglutide was on the FDA drug shortage list (2022 to 2025), allowing licensed compounding pharmacies to produce it under specific regulatory conditions. On February 21, 2025, the FDA issued a Declaratory Order declaring the semaglutide shortage resolved for all presentations. Enforcement deadlines for compounders passed on April 22, 2025 (503A pharmacies) and May 22, 2025 (503B outsourcing facilities). On April 30, 2026, the FDA proposed permanently excluding semaglutide from the 503B bulk drug substances list. Patients currently using or considering compounded semaglutide should understand the current regulatory status, the differences from FDA-approved products, and the documented safety concerns that have emerged since widespread use began.
What Is Compounded Semaglutide and How Is It Different?
Pharmaceutical compounding is the practice of a licensed pharmacy preparing a medication for an individual patient when a commercially available product does not meet that patient’s specific needs. Traditionally, compounding serves patients with allergies to excipients, those requiring non-standard doses, or those needing formulations not available commercially (for example, liquid versions of medications that only come as tablets).
Compounded semaglutide refers to semaglutide prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. The resulting product is not Wegovy or Ozempic. It is a pharmacy-prepared preparation that may contain semaglutide as an active ingredient but has not been evaluated by the FDA for safety, efficacy, purity, or potency. Key differences from FDA-approved products include:
- Chemical form: FDA-approved Wegovy and Ozempic use semaglutide in its base form. Most compounded preparations use semaglutide acetate or semaglutide sodium — salt forms whose pharmacokinetics, bioavailability, and safety have not been established in humans through clinical trials.
- Manufacturing standards: Novo Nordisk’s manufacturing is subject to FDA Current Good Manufacturing Practice (cGMP) inspections and rigorous quality controls. Compounding pharmacy standards vary by facility and are subject to state board of pharmacy oversight and, for 503B outsourcing facilities, FDA inspections — but not to the same cGMP requirements as pharmaceutical manufacturers.
- Batch consistency: Each compounding batch may vary in concentration, sterility, and stability. There is no requirement for compounded semaglutide to demonstrate consistent potency across batches.
- No clinical trial data: Compounded semaglutide has not been studied in randomized controlled trials. The efficacy and safety data from STEP-1 and SELECT apply only to Novo Nordisk’s semaglutide formulation.
In October 2024, the FDA issued a formal warning stating that it had received more than 455 adverse event reports related to compounded semaglutide, including hospitalization and, in some cases, death. The FDA identified dosing errors as a primary contributing factor, including patients self-administering incorrect doses due to imprecise or unclear labeling on compounded products. The FDA specifically noted concerns about products labeled in units (U) of insulin syringes rather than milligrams (mg), creating 10-fold dosing errors in some patients. The FDA advised patients to verify that any semaglutide they receive comes from a licensed, reputable source and to confirm the product’s labeling clearly states the dose in milligrams.
The Legal Status of Compounded Semaglutide in 2025 and 2026
The legal framework for compounded semaglutide has changed significantly since the shortage period ended. Understanding the current regulatory status is essential for any patient or prescriber involved with compounded products.
The shortage period (2022 to 2024)
When the FDA places a drug on its drug shortage list, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit licensed compounding pharmacies to compound copies of shortage drugs under specific conditions. Semaglutide’s placement on the shortage list from 2022 to 2024 created the legal basis for widespread compounding. During this period, hundreds of compounding pharmacies began producing semaglutide preparations, and telehealth companies built business models around prescribing compounded semaglutide at significantly lower prices than FDA-approved products.
After shortage removal (February 2025 onwards)
On February 21, 2025, the FDA issued a Declaratory Order declaring the semaglutide shortage resolved for all presentations. Enforcement deadlines were set at April 22, 2025 for 503A state-licensed pharmacies and May 22, 2025 for 503B outsourcing facilities. The Outsourcing Facilities Association (OFA) filed a lawsuit challenging the determination on February 24, 2025, but on March 5, 2025, the U.S. District Court for the Northern District of Texas denied their motion for a preliminary injunction. This confirmed the FDA’s position that routine compounding of semaglutide as “essentially a copy” of the approved products was no longer legally permissible.
In September 2025, the FDA issued more than 50 warning letters to companies compounding or manufacturing GLP-1 medications including semaglutide. On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list — a move that would permanently close large-scale compounding of these agents with no regulatory pathway for reinstatement.
The legal landscape for compounded semaglutide continued to evolve through 2025 and into 2026, including ongoing litigation between compounding pharmacies and the FDA. Patients currently using compounded semaglutide should verify the current legal status with their prescribing physician and confirm that their pharmacy is operating under a legitimate legal basis. This article reflects the regulatory situation as of July 2026 and may not capture subsequent changes.
Safety Concerns: What the Data and Reports Show
The safety concerns with compounded semaglutide fall into two categories: issues inherent to the compounding process itself, and issues specific to the product types and practices that emerged during the shortage period.
Dosing errors
The most consistently documented safety issue with compounded semaglutide is dosing error. FDA-approved Wegovy comes in prefilled, single-dose pens with the dose clearly set and no calculation required. Compounded semaglutide is typically supplied as multi-dose vials requiring the patient to draw their own dose using an insulin syringe. This creates multiple points of potential error: misreading the volume, confusing units and milligrams, incorrect syringe calibration, and inadequate escalation instructions.
The FDA’s October 2024 adverse event report identified multiple cases of patients receiving 10-fold overdoses because the labeling used units (U) rather than milligrams (mg) and patients used insulin syringes calibrated in different units. Overdoses of semaglutide produce severe nausea, vomiting, hypoglycemia in susceptible patients, and potential for serious dehydration.
Potency and concentration variability
Independent testing of compounded semaglutide products has found variability in actual semaglutide concentration vs. labeled concentration across batches and facilities. A product labeled at 5mg/mL may contain 3mg/mL or 7mg/mL depending on the compounding facility’s quality controls and the starting material used. This variability means patients may receive more or less drug than intended, with neither the patient nor the prescriber aware of the deviation.
Sterility
Compounded injectable preparations must be sterile. The FDA has identified sterility failures at some compounding facilities during inspections. Sterility failures in injectable products can cause serious local infections, abscesses, or systemic sepsis. Patients should only use compounded injectables from facilities with documented sterility testing and, for 503B facilities, FDA inspection records.
Compounded vs. FDA-Approved Semaglutide: Key Differences
| Factor | FDA-Approved (Wegovy / Ozempic) | Compounded Semaglutide |
|---|---|---|
| FDA review | Full NDA review: safety, efficacy, manufacturing | Not FDA-reviewed; no NDA required |
| Chemical form | Semaglutide base (studied in all trials) | Usually semaglutide acetate or sodium salt (not clinically studied) |
| Potency consistency | Guaranteed by cGMP manufacturing | Variable; batch-to-batch differences documented |
| Delivery device | Pre-filled single-dose autoinjector pen | Multi-dose vial requiring patient self-drawing |
| Clinical trial evidence | STEP-1 to STEP-8, SELECT, ESSENCE trials | None specific to compounded formulation |
| Legal status (2026) | FDA-approved; legal to prescribe for approved indications | Legally restricted after shortage removal; ongoing litigation |
| Cost (approximate) | $1,000 to $1,349/month list price; lower with insurance | $150 to $400/month (highly variable by provider) |
The Semaglutide Salt Form Issue: Why It Matters
One of the least-publicized but most clinically significant differences between compounded and FDA-approved semaglutide is the chemical form of the active ingredient. This is not a minor technical distinction — it has direct implications for how the drug behaves in the body.
Wegovy and Ozempic contain semaglutide in its base (free acid) form. This is the form that was used in all STEP trials, the SELECT cardiovascular trial, and all other published clinical studies. The pharmacokinetics, dosing schedule, efficacy data, and side effect profile that patients and physicians rely on all apply to this specific molecular form.
Most compounded semaglutide uses semaglutide acetate or semaglutide sodium — salt forms that are chemically distinct from the base form. The FDA has explicitly stated that it considers these to be different drug substances from the semaglutide in approved products. The pharmacokinetics of semaglutide acetate or sodium in humans have not been established through clinical trials. This means patients using compounded salt-form semaglutide are, in effect, using a drug that has not been studied for its specific behavior in the human body at the doses being administered.
Who Has Been Using Compounded Semaglutide and Why
The primary driver of compounded semaglutide use has been cost. At $150 to $400 per month vs. $1,000 to $1,349 for FDA-approved products, compounded versions were significantly more affordable, particularly for the large proportion of patients without insurance coverage for weight management medications.
The populations who used compounded semaglutide during the shortage period were broadly the same patients who would benefit from approved semaglutide: adults with obesity or overweight and weight-related comorbidities. Many experienced weight loss. The question is not whether weight loss can occur with compounded semaglutide — it likely can, if the product contains active semaglutide at a reasonable concentration. The question is whether patients can be confident of what they are receiving, at what dose, and whether the product is safe from a sterility and contamination standpoint.
Should You Use Compounded Semaglutide? Decision Framework
Cost Alternatives to Compounded Semaglutide
The most common reason patients seek compounded semaglutide is cost. Several options can reduce the cost of FDA-approved semaglutide significantly, making the risk-benefit comparison less compelling for choosing the compounded alternative.
Novo Nordisk savings programs: The NovoCare savings program for Wegovy can reduce monthly costs to as low as $25 for eligible commercially insured patients. Ozempic has similar savings programs. Eligibility depends on insurance type and household income.
Insurance prior authorization: Commercial insurance increasingly covers Wegovy for patients with confirmed BMI criteria and, post-SELECT trial, for patients with obesity and cardiovascular disease. A successful prior authorization approval eliminates out-of-pocket cost beyond copay.
Tirzepatide as an alternative: Zepbound (tirzepatide) vials are available through Eli Lilly’s self-pay program at significantly lower cost than Wegovy, and tirzepatide produces greater average weight loss (approximately 20% vs. 15%). For patients without insurance coverage, Zepbound’s self-pay vial program may be a more cost-effective FDA-approved option than compounded semaglutide. For a full comparison, see our guide on tirzepatide vs. semaglutide: which weight loss injection wins.
Telehealth subscription programs: Several telehealth platforms provide physician oversight, prior authorization assistance, and prescription management for FDA-approved GLP-1 medications at flat monthly rates that include the clinical support typically billed separately by traditional clinics. This reduces the total cost of supervised FDA-approved therapy. For details on how a structured weight loss programme compares to self-managed compounded use, see our overview of semaglutide for weight management: evidence-based dosing and expectations.
Get Evaluated for FDA-Approved Weight Loss Therapy
Advanced TRT Clinic provides physician-supervised weight management via telemedicine using FDA-approved medications, including tirzepatide and semaglutide-based protocols. All prescriptions are for commercially manufactured, FDA-approved products. We do not prescribe compounded semaglutide. Availability varies by state.
